Serotonin 5HT2C Agonist Drugs with 5HT2A/2B Antagonist Activity
具有 5HT2A/2B 拮抗活性的血清素 5HT2C 激动剂药物
基本信息
- 批准号:7769452
- 负责人:
- 金额:$ 32.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-08 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAddressAdultAffinityAgeAgonistAmino AcidsAmphetaminesAnimalsBehaviorBindingBody Weight decreasedBrainCardiacCardiovascular DiseasesCattleCellsChemicalsChildDataDevelopmentDiabetes MellitusDiseaseDockingDrug EvaluationEatingElectronicsElectrostaticsEvaluationG-Protein-Coupled ReceptorsHomology ModelingHumanIn VitroInhibitory Concentration 50Inositol PhosphatesKnock-outLeadLigandsLocomotionMalignant NeoplasmsMapsMembraneMental DepressionModelingMolecularMolecular ConformationMolecular Mechanisms of ActionMolecular ModelsMorbidity - disease rateMusMutagenesisMutateMutationObesityOutcomeOverweightPeripheralPharmaceutical PreparationsPharmacotherapyPhospholipase CPoint MutationPositioning AttributePsychotic DisordersPulmonary HypertensionQuantitative Structure-Activity RelationshipReceptor SignalingRecombinantsRelative (related person)ReportingResearchRoleSerotoninStructureStudy modelsTestingTetrahydronaphthalenesanalogattenuationbasecardiovascular disorder riskchemical synthesiscomputational chemistrydrug structuredrug testingfood consumptionin vivoinnovationmolecular modelingmolecular recognitionneurobehavioralneuropsychiatrypharmacophorepre-clinicalpreclinical evaluationpreclinical studypsychologicpublic health relevancereceptorreceptor bindingrhosocialthree dimensional structure
项目摘要
DESCRIPTION (provided by applicant): There is compelling evidence that activation of brain serotonin 5HT2C G protein-coupled receptors (GPCRs) produces anti-obesity effects in humans, attenuation of psychomimetic activity, and other neuropsychiatric effects. Meanwhile, activation of brain 5HT2A GPCRs produces psychomimetic effects and activation of peripheral 5HT2B GPCRs produces cardiac valvulopathy and pulmonary hypertension. Currently, there is no 5HT2C receptor agonist reported that does not also activate 5HT2A and/or 5HT2B receptors. This research proposes to exploit a compound synthesized in our lab, (1R,3S)-(-)-trans-1-phenyl-3-dimethylamino-1,2,3,4- tetrahydronaphthalene (PAT), that is a full-efficacy agonist at human 5HT2C receptors, plus, it is an antagonist at 5HT2A and 5HT2B receptors. As a small (MW=250) lipophilic molecule, (-)-trans-PAT readily penetrates mouse brain after peripheral (IP) administration to inhibit food consumption, produce weight loss, and inhibit amphetamine-induced locomotion, neurobehavioral effects consistent with 5HT2C agonism and 5HT2A antagonism. This research proposes preclinical evaluation of (-)-trans-PAT as pharmacotherapy for obesity and neuropsychiatric disorders, and, synthesis of other PATs with potent and efficacious 5HT2C agonist activity; PATs with potent 5HT2A/5HT2B antagonism may be lead drugs for psychiatric or cardiovascular diseases. We also have identified a potent PAT-type 5HT2C inverse agonist useful especially to characterize molecular determinants involved in ligand-directed 5HT2C function. Targeted medicinal chemical syntheses will provide PAT type stereo-probes as test drugs for preclincial evaluation and to map molecular determinants for 5HT2C binding/activation for inferences of receptor 3D structure. Forty PATs already are available and 32 new analogs will help delineate the PAT- 5HT2C pharmacophore - the optimal PAT steric, lipophilic, and electronic chemical molecular features. In vitro binding/functional studies will continue to be conducted using clonal cells expressing recombinant human 5HT2A, 5HT2B, or 5HT2C receptors - preliminary results and PAT-5HT2C 3D QSAR and receptor homology models lead us to propose construction and expression of D3.32A, S3.36A, A5.46N, A5.46S, F5.47A, F5.48A, W6.48A, F6.51A, F6.52A, Y7.43A, & Y7.53A point-mutated 5HT2C receptors to validate hypothesized PAT- 5HT2C binding/function interactions. In an iterative fashion, pharmacological results and molecular models generate additional hypotheses to test involving additional PAT syntheses and 5HT2C point-mutations for receptor characterization and development of PAT-type 5HT2C agonist drug structures. Preclinical studies to evaluate PATs as pharmacotherapy for obesity, eating and other neuropsychiatric disorders, as well as, to determine in vivo molecular mechanisms of action, are conducted using wild-type vs. genetically modified mice with global disruption ("knock-out") of 5HT2C and 5HT2A receptor signaling. PUBLIC HEALTH RELEVANCE: About 65% of adults and 16% of children aged 6-19 years in the U.S. currently (2005) are overweight or obese. Obesity is associated with increased risk for cardiovascular disease; diabetes; certain forms of cancer, depression, and various other physical, psychological, and social morbidities. Current pharmacotherapy available for obesity is unsatisfactory. This research seeks to develop new drugs to treat obesity, as well as, certain neuropsychiatric disorders.
描述(由申请人提供):有令人信服的证据表明,脑5-羟色胺5 HT 2C G蛋白偶联受体(GPCR)的激活可在人体中产生抗肥胖作用、减弱拟精神活动和其他神经精神作用。同时,脑5 HT 2A GPCR的激活产生拟精神效应,外周5 HT 2B GPCR的激活产生心脏瓣膜病和肺动脉高压。目前,没有报道不激活5 HT 2A和/或5 HT 2B受体的5 HT 2C受体激动剂。本研究拟开发本实验室合成的一种化合物(1 R,3S)-(-)-trans-1-phenyl-3-dimethylamino-1,2,3,4- tetrahydronaphthalene(PAT),该化合物是人5 HT_(2C)受体的全效激动剂,同时也是5 HT_(2A)和5 HT_(2B)受体的拮抗剂。作为一种小的(MW=250)亲脂性分子,(-)-trans-PAT在外周(IP)给药后容易穿透小鼠脑,以抑制摄食,产生体重减轻,并抑制苯丙胺诱导的运动,神经行为效应与5 HT 2C激动和5 HT 2A拮抗作用一致。本研究提出了(-)-trans-PAT作为肥胖和神经精神疾病药物治疗的临床前评价,以及具有强效和有效的5 HT 2C激动剂活性的其他PAT的合成;具有强效5 HT 2A/5 HT 2B拮抗作用的PAT可能是精神或心血管疾病的先导药物。我们还鉴定了一种有效的PAT型5 HT 2C反向激动剂,特别适用于表征参与配体导向的5 HT 2C功能的分子决定簇。靶向药物化学合成将提供PAT型立体探针作为临床前评价的试验药物,并绘制5 HT 2C结合/激活的分子决定簇,以推断受体3D结构。已经有40种PAT可用,32种新的类似物将有助于描述PAT-5 HT 2C药效团-最佳PAT空间,亲脂性和电子化学分子特征。将继续使用表达重组人5 HT 2A、5 HT 2B或5 HT 2C受体的克隆细胞进行体外结合/功能研究-初步结果和PAT-5 HT 2C 3D QSAR和受体同源性模型使我们提出D3.32A、S3.36A、A5.46N、A5.46S、F5.47A、F5.48A、W6.48A、F6.51A、F6.52A、Y7.43A和Y7.53A点突变的5 HT 2C受体以验证假设的PAT-5 HT 2C结合/功能相互作用。以迭代的方式,药理学结果和分子模型产生额外的假设,以测试涉及额外的PAT合成和5 HT 2C点突变的受体表征和PAT型5 HT 2C激动剂药物结构的开发。评价PAT作为肥胖症、进食和其他神经精神障碍的药物疗法以及确定体内分子作用机制的临床前研究使用具有5 HT 2C和5 HT 2A受体信号传导的整体破坏(“敲除”)的野生型小鼠与遗传修饰的小鼠进行。公共卫生相关性:目前(2005年),美国6-19岁的成年人和儿童中约有65%超重或肥胖。肥胖与心血管疾病、糖尿病、某些形式的癌症、抑郁症和各种其他身体、心理和社会疾病的风险增加有关。目前可用于肥胖症的药物治疗是不令人满意的。这项研究旨在开发新的药物来治疗肥胖症,以及某些神经精神疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Raymond G. Booth其他文献
“Selective” serotonin 5-HTsub2A/sub receptor antagonists
选择性 5-羟色胺 5-HT2A 受体拮抗剂
- DOI:
10.1016/j.bcp.2022.115028 - 发表时间:
2022-06-01 - 期刊:
- 影响因子:5.600
- 作者:
Austen B. Casey;Meng Cui;Raymond G. Booth;Clinton E. Canal - 通讯作者:
Clinton E. Canal
A novel 5HT2C-specific agonist/5HT2A-2B antagonist attenuates psychomotor behaviors induced by methamphetamine, oxycodone, and their combination
- DOI:
10.1016/j.drugalcdep.2014.09.497 - 发表时间:
2015-01-01 - 期刊:
- 影响因子:
- 作者:
Drake Morgan;Clinton E. Canal;Paul C. Orza;Jessica L. Rose;Myong S. Kim;Raymond G. Booth - 通讯作者:
Raymond G. Booth
Raymond G. Booth的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Raymond G. Booth', 18)}}的其他基金
Training Program on Development of Medications for Substance Use Disorder
药物滥用药物开发培训计划
- 批准号:
10630338 - 财政年份:2022
- 资助金额:
$ 32.91万 - 项目类别:
Training Program on Development of Medications for Substance Use Disorder
药物滥用药物开发培训计划
- 批准号:
10411562 - 财政年份:2022
- 资助金额:
$ 32.91万 - 项目类别:
Delineating the role of serotonin 5-HT2 receptors in opioid use disorders:Development of novel 5-HT2 modulators with translational studies in rodents andprimates
描述血清素 5-HT2 受体在阿片类药物使用障碍中的作用:通过啮齿类动物和灵长类动物的转化研究开发新型 5-HT2 调节剂
- 批准号:
10164749 - 财政年份:2018
- 资助金额:
$ 32.91万 - 项目类别:
Delineating the role of serotonin 5-HT2 receptors in opioid use disorders:Development of novel 5-HT2 modulators with translational studies in rodents andprimates
描述血清素 5-HT2 受体在阿片类药物使用障碍中的作用:通过啮齿类动物和灵长类动物的转化研究开发新型 5-HT2 调节剂
- 批准号:
10410391 - 财政年份:2018
- 资助金额:
$ 32.91万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8312648 - 财政年份:2010
- 资助金额:
$ 32.91万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8531900 - 财政年份:2010
- 资助金额:
$ 32.91万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8715749 - 财政年份:2010
- 资助金额:
$ 32.91万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8144930 - 财政年份:2010
- 资助金额:
$ 32.91万 - 项目类别:
Serotonin 5HT2C Agonist Drugs with 5HT2A/2B Antagonist Activity
具有 5HT2A/2B 拮抗活性的血清素 5HT2C 激动剂药物
- 批准号:
8231473 - 财政年份:2008
- 资助金额:
$ 32.91万 - 项目类别:
Serotonin 5HT2C Agonist Drugs with 5HT2A/2B Antagonist Activity
具有 5HT2A/2B 拮抗活性的血清素 5HT2C 激动剂药物
- 批准号:
8029498 - 财政年份:2008
- 资助金额:
$ 32.91万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 32.91万 - 项目类别:
Research Grant